Board of Directors

Marc Coucke
Chairman, Non-executive Director

Marc-Coucke

Mr Coucke holds a degree in Pharmacy (University Ghent) and an MBA (Vlerick Management School, Ghent).

He is the founder of Omega Pharma. Until September 2006, he held both the position of CEO and Chairmen of Omega Pharma.

After the acquisition of Omega Pharma by Perrigo, he became Executive VP of Perrigo and CEO of Omega Pharma.

François Fornieri
Executive Director

Mr Fornieri has over 25 years of pharmaceutical experience with a strong focus on women’s health.He obtained a degree in Chemistry and is the founder and CEO of the Company.

François previously worked for Bayer-Schering and was also a co-founder of Uteron Pharma, which was sold to Watson/Actavis (NYSE: ACT) early 2013.

François has been elected the French speaking “2011 Manager of the year” by the Belgian business magazine Trends/Tendances.

Jean-Michel Foidart
Executive Director

Prof Jean-Michel Foidart co-founded Mithra Pharmaceuticals SA and Uteron Pharma SA.

Through his membership of international research centers, his academic and industry career, he has extensive knowledge of reproductive medicine.

He trained in Gynecology at the University of Liège where he also obtained a PhD in cell biology and biochemistry. He was the former head of the Gynecology and Obstetrics department at the University of Liège, the general secretary of the European Society of Gynaecology (ESG) and member of multiple editorial boards of international peer-reviewed journals.

Prof Foidart was awarded the Bologne-Lemaire Prize from Institut Destrée (Walloon of the year) in 2011.

Koen Hoffman
Independent Director

koen-hoffmanMr. Hoffman obtained a Master in Applied Economics at the University of Ghent in 1990 and a Master in Business Administration at Vlerick Business School in Ghent in 1991. He started his career at the corporate finance department of KBC Bank in 1992.

He was Chief Executive Officer of KBC securities NV from October 2012 to July 2016. He also served as a Member of Supervisory Board at KBC IFIMA S.A. (formerly, KBC Internationale Financieringsmaatschappij N.V.) and at Patria Securities, and as a Member of The Board of Directors of Omnia Travel Belgium.

Mr. Hoffman has been Chief Executive Officer of Value Square and Independent Director of Fagron NV since August 2016.

Christiane Malcorps
Independent Director

Christiane Malcorps ir. PhD, is currently Country Manager for Belgium and Global Head of Facility Excellence for SOLVAY SA.

After receiving a Master in Chemical Engineering at KU Leuven and a PhD at the University of Wisconsin, Madison, USA, she occupied applied and fundamental research positions at different universities in USA and Belgium and entered SOLVAY S.A. in 1984. She was assigned within SOLVAY several Research, Development and Technology functions first with local and later on with international responsibilities in the fields of biopesticides, enzymes and vaccines. In 1997 she was based in the SOLVAY plants in Antwerp and became in 2005 Site Director of the Antwerp complex for SOLVAY producing polyolefines and chlorine. Always striving for excellence she became country manager for Belgium in 2009. During her career she was trained as executive in the business schools of INSEAD & IMD.

Christiane Malcorps is member of the Board of several professional and other organizations in Belgium (essenscia, UWE, BECI, The Shift, Degraeve Antwerpia).

Jacques Platieau
Independent Director

Jacques-Platieau

Mr Jacques Platieau began his career at IBM Belgium in the Telecommunications division as System & Sales Engineer. From 1990 to 1994 he was Client Executive for major international clients. In 1995, Jacques became SWG Sales Manager Belgium/Luxembourg and in 1997 SWG Executive for Belgium/Luxembourg. In 1998, he had in parallel the lead of the Software Group at IBM France as Sales Director. In July 2002, Mr Platieau became Director of the Data Management and Business Intelligence System for the West region. In July 2003, he joined the Business Consulting practice of IBM as Practice Area Leader for the Industrial Section and in April 2005 became General Manager of IBM Global Business Services for Belgium/Luxembourg. Since July 2005, Mr Platieau has been General Manager of IBM Global Business Services for the Benelux. On April 6th 2010, Mr. Platieau was named Country General Manager for IBM Belgium/Luxembourg and Sector Leader Benelux.

Mr Platieau holds a degree in Mathematics and Computer Sciences from the University of Mons-Hainaut, Belgium.

Jacques Platieau is board member of various associations, UWE, VOKA, BECI and Agoria. He is Vice-President of Futurocité in Mons and President of the Basket Ball Club of Braine.

Philippe Suinen
Independent Director

Philippe-Suinen

Mr Suinen holds a degree in law from the University of Liège and a graduate diploma in European law from the University of Nancy.

He entered public service in 1974 via the Government Recruitment Service and started his career at the Belgian Ministry of Foreign Affairs. From 1998 to 2014, he was CEO of A.W.E.X, General Administrator of WBI (Wallonia Brussels International) and APEFE (Association for the Promotion of Education and Training Abroad) and Senior Lecturer at the ULB (Free Brussels University). In 2014, he was elected President of the Chamber of Commerce and Industry of Wallonia (CCIW).

During his career, he also served in several ministerial cabinets (Institutional Reforms, Education, Presidency of the Walloon Government and, as Chief of Cabinet, Foreign Trade and European Affairs, Vice-Presidency of the Belgian Federal Government, including transport, public enterprises, economy and telecommunications). He was also Vice-Chairman of the Board of SABENA and “Walloon of the Year” in 1999.

Patricia van Dijck
Independent Director

Patricia van Dijck has a degree in medicine and a specialization in clinical biology and pharmaceutical medicine from the Catholic University of Louvain (UCL).

She began her career in the pharmaceutical industry in 1996 as an International Medical Advisor at UCB. In 1998, she became Medical Director at Lundbeck, before being appointed to the position of Managing Director in 2007. In 2011, Ms. van Dijck joined Novartis Belux as Head of Market Access & Public Affairs, before joining the mother company in Basel in 2014, in order to assume the position of Head Patient Access Excellence. Three years later, she became Project Lead of an IMI project of European private-public partnership in hemato-oncology, in Milan. Since 2018, she has worked for GSK Belux as a Market Access & Public Affairs Director.

Throughout her career in the pharmaceutical industry, Patricia van Dijck has developed a solid experience in the different life cycle areas of a drug.

Guy Debruyne
Non-executive Director

Guy-de-Bruyne

Mr Debruyne takes care of the family patrimony since 1975.

He is involved as a private investor in real estate construction companies, renewable energy development companies and the Company.

Freya Loncin
Non-executive Director

freya-loncin-285x285

Ms. Freya Loncin serves as General Counsel of Alychlo NV. Ms. Loncin served as Head of Legal at Omega Pharma NV and TVH NV after starting her career as a lawyer at Allen & Overy LLP.

She has a broad experience incorporate law, mergers and acquisitions and commercial agreements. She serves as a Non-Executive Director of Fagron NV. Ms. Loncin is a graduate of the University of Antwerp (Law).

Christian Moretti
Non-executive Director

Graduated from HEC Paris and from Columbia Business School (MBA), Christian Moretti begins his career in Finance at Paribas (Industrial dep.) where he was active for over 10 years.

He founded Dynaction SA, a diversified industrial holding listed on the Paris Stock Exchange, with several subsidiaries listed on the second Parisian market. Christian Moretti then focused on the development of one of these 7 subsidiaries, PCAS Biosolution SA, where he was president for 13 years. PCAS is a European leader in complex molecules chemistry, employing more than 1000 people worldwide and whose pharmaceutical contract manufacturing represents 60% of its global activity.

After the acquisition of PCAS by Novacap (Sequens group) in June 2017, Mr. Moretti became shareholder at Mithra as an Observor, then as Director.

Christian Moretti was also Professor of Finance at ESCP Europe Campus Paris and represented France at CEFIC (European syndicat of Chemistry in Bruxelles).

Gaëtan Servais
Non-executive Director

Gaetan-Servais

Mr Servais holds a Master Degree in Economics at the University of Liège.

He started his career as Research Assistant at the University of Liège.

In 1995, Gaëtan joined the Federal Planning Bureau as Expert and later the Economic and Social Council of the Walloon Region. Since 2001, he was chief of staff for several ministers of the Walloon Government.

Since 2007 he has been CEO of Meusinvest, a financial company that has structured its activity in different subsidiaries to better respond to business financing needs of small and medium enterprises (SME) located in the province of Liège.

Joanna Tyrekidis
Non-executive Director

Joanna Tyrekidis is currently Investment Manager for the NOSHAQ Group, a multi-sector investment fund based in Liège, Belgium. She manages a portfolio of companies in the field of engineering and life sciences. Pharmaceutical companies, biotechnology companies and the medical device field especially are part of her areas of expertise. She sits on the Board of Directors of a dozen companies active in these sectors.

Mrs. Tyrekidis holds a Master’s degree in Management Sciences from the University of Liège. She has more than 10 years of experience in the field of strategic and financial consulting for technology companies through her previous professional activities in Belgium and abroad. She also led the AWEX’s commercial office in Amman from 2010 to 2013.

Michaël Dillen
Company Secretary

Mr. Dillen has gained a vast experience in healthcare through various both corporate and legal positions. Before joining Mithra Michaël worked for Terumo, a Japanese stock listed MedTech and pharma company. Here, he acted as senior counsel responsible for covering legal services in the EMEA region. He initiated his career as a lawyer, where he developed a legal practice focusing on corporate and commercial advisory towards both private and institutional clients in the life sciences industry.

Michaël holds law degrees (LL.M.) in both health law and in business law (University of Antwerp and Queen Mary and Westfield College, University of London), as well as a degree in business (Solvay Business School) and corporate finance (Saïd Business School, University of Oxford).

Executive Management

François Fornieri

Chief Executive Officer (CEO) – Chief Business Development Officer (CBDO)

Mr François Fornieri has almost 30 years of pharmaceutical experience with a strong focus on women’s health. He obtained a degree in Chemistry and is the founder and CEO of the Company.

François previously worked for Bayer-Schering and was also a co-founder of Uteron Pharma, which was sold to Watson/Actavis (NYSE: ACT) early 2013.

François has been elected the French speaking “2011 Manager of the year” by the Belgian business magazine Trends/Tendances.

Mr Christophe Maréchal was Director, Group Treasury and Credit Risk Management, at Hamon Group (Euronext Brussels: HAMO), an engineering and contracting company. He has more than 20 years of international financial experience in the industrial, telecommunications, manufacturing and banking  industries, including M&A, operational and financial strategy, and tactical initiatives to drive long-term business growth.

Before joining Hamon Group in 2006, Mr Maréchal held a number of positions at France Telecom Group in Paris, London and Brussels, including Deputy Group Treasurer. He holds a Masters in Business Administration from the University of Liège, Belgium, and studied econometrics at the Katholieke Universiteit Brabant, Tilburg, Netherlands.

Christophe Maréchal

Chief Financial Officer

Michaël Dillen

CLO & VP Corporate Development

Mr. Dillen has gained a vast experience in healthcare through various both corporate and legal positions. Before joining Mithra Michaël worked for Terumo, a Japanese stock listed MedTech and pharma company. Here, he acted as senior counsel responsible for covering legal services in the EMEA region. He initiated his career as a lawyer, where he developed a legal practice focusing on corporate and commercial advisory towards both private and institutional clients in the life sciences industry.

Michaël holds law degrees (LL.M.) in both health law and in business law (University of Antwerp and Queen Mary and Westfield College, University of London), as well as a degree in business (Solvay Business School) and corporate finance (Saïd Business School, University of Oxford).

Dr Graham Dixon has a 27 year international career in the pharmaceutical industry, with a strong track record in R&D across many therapeutic areas.  He also has solid leadership experience having worked across a number of R&D management positions at AstraZeneca plc and in C-level management positions in several biotech companies:  Entomed SA;  Galapagos NV (AMS:GLPG);  Addex Therapeutics SA (SWX:ADXN);  Sensorion SA (EPA:ALSEN) and Onxeo SA (EPA:ONXEO).

Dr Dixon has also held leadership roles in successful programmes spanning the whole continuum of R&D, including clinical proof-of-concepts and regulatory approvals. On the business side, he has held executive roles in two successful IPOs (Galapagos & Sensorion) and 10 clinical stage licensing deals.

He has also held several non-executive director positions in the biotech sector and acted as an advisor to several venture capital organisations and their portfolio companies.

Dr Dixon obtained a Bachelor’s degree in Biology from the University of Bradford, UK and a PhD in Biochemistry from the University of Swansea, UK.

Graham Dixon

Chief Scientific Officer (CSO)

Jean-Michel Foidart

President of the Scientific advisory board

Prof Jean-Michel Foidart co-founded Mithra Pharmaceuticals SA and Uteron Pharma SA.

Through his membership of international research centers, his academic and industry career, he has extensive knowledge of reproductive medicine.

He trained in Gynecology at the University of Liège where he also obtained a PhD in cell biology and biochemistry. He was the former head of the Gynecology and Obstetrics department at the University of Liège, the general secretary of the European Society of Gynaecology (ESG) and member of multiple editorial boards of international peer-reviewed journals.

Prof Foidart was awarded the Bologne-Lemaire Prize from Institut Destrée (Walloon of the year) in 2011.

Mr Fontaine has over 18 years of experience in the pharma industry in manufacturing, supply chain and commercial positions.

He started his career at Pfizer in supply chain and manufacturing where he ensured ERP implementation and integration of Pfizer’s Belgium manufacturing site. In 2001 he joined Lundbeck where he held various positions in sales & marketing in Belgium and France, notably for Cipralex® product. In 2010, Jean-Manuel joined UCB global marketing team as associate director developing global campaign for the brand and driving business alignment across EU regions.

In 2013, Jean-Manuel joined Mithra to lead successively business development and public relations.

Jean-Manuel holds a Master in Pharmaceutical Sciences and MBA from Cornell University.

Jean-Manuel Fontaine

VP External
& Scientific Affairs

Alexandra Deschner

Investor Relations Officer

Alexandra Deschner joins Mithra as Investor Relations Officer where she will be responsible for the investor strategy, together with the successful communication of the company’s equity story to the investment community.

Alexandra has nearly 20 years combined international experience across a variety of functions and sectors, including pharmaceutical, automotive, banking, and insurance.  She joins Mithra from UCB, where she held a number of roles, most recently as Director of Corporate Social Responsibility, where she was responsible for the implementation and management of several new patient initiatives in Africa. Prior to this she was Director of R&D Portfolio Management and Director of Investor Relations at UCB.

Born and raised in the United States, Alexandra holds an M.B.A. in International Management from Fordham University in New York and a Bachelor’s degree in International Business from Loyola College in Maryland.

M. Brands holds a bachelor’s degree from the university of Liège ( Belgium) in Public Health with a major in Epidemiology and Health Economics and has over 10 years’ experience in the pharmaceutical industry. His area of expertise covers Regulatory Affairs, Quality Assurance and Supply Chain.

M. Brands started his career at Astra Zeneca in a commercial role and joined Mithra in 2009 to take growing responsibilities in the Quality Assurance and Regulatory Affairs department. After developing the Quality Assurance activity at Mithra as QA Manager he progressively transitioned to Supply Chain Manager to develop the whole Supply activities and manage the growing logistic and supply streams.

His deep knowledge of the logistical organisation within the company together with his sound experience in establishing and developing the Supply Chain activity allows M. Brands to take the role as Chief Supply Chain Officer at Mithra. In this position M. Brands will address the Mithra CDMO logistic and supply development , which is key to the company’s growth.

Benjamin Brands

Chief Supply Chain Officer

Patrick Kellens

Chief Information Officer

Mr Kellens has more than 25 years of IT experience in different sectors like health, telecommunications, consulting and manufacturing. He also has 5 years experience in the pharmaceutical industry as clinical data manager inside a clinical pharmacology unit at Eli Lilly.

Before joining Mithra in 2018, he held various positions ranging from consultant, project/program manager, operations manager to finally IT manager in a large local healthcare institution. He holds a Master degree in Biochemistry from the University of Liège and a complementary degree in IT.

Corporate Governance Charter